1. Introduction {#sec1}
===============

Bioavailable 17*β*-estradiol correlates with the bone mineral density (BMD). On the contrary, an estrogenic lack determines a condition characterized by the prevalence of bone reabsorption phase over the bone formation phase. Osteoporosis in postmenopause recognizes also low serum 1,25(OH)~2~D levels and a reduced intestinal transport of calcium, always due to the estrogenic lack. The reabsorption markers increase up to two times the values seen in premenopause, while values of bone formation markers increase only by 50% \[[@B1]\]. The biochemical indicators of increased osteoblastic activity are represented by the serum levels of osteocalcin and of alkaline phosphatase, while the urinary levels of hydroxyproline are expression of an increased osteoclastic activity. In presence of an accelerated bone replacement, osteocalcin and alkaline phosphatase serum levels and urinary hydroxyproline excretion are increased. The diagnosis of osteopenia and/or osteoporosis is conventionally made by measuring bone densitometry. There is a wide debate concerning the effects of the treatment with L-thyroxin (LT4) on BMD. Thyroid hormones certainly determine an increase of both osteoblastic and osteoclastic activities over both cortical and trabecular bones \[[@B2], [@B3]\]. However, the data about the real impact that LT4 therapy exerts on BMD of women subjected to prolonged periods of treatment appear contrasting. In particular, an approach built on the preventive determination of the anamnestic profile considered at risk for bone demineralization in women undergoing LT4 use is lacking. Hyperthyroidism has been associated with bone demineralization \[[@B3]--[@B7]\]. Studies in vitro suggest that thyroid hormones increase more the re-absorption than bone formation, hence determining a loss of bone mass \[[@B8], [@B9]\]. It has also been reported how thyrotoxicosis increases the fracture risk in post-menopause women and in patients with low bone mass peak. Fractures are more frequent in those parts of the skeleton in which predominates the cortical bone, such as the hip and the distal part of the arm \[[@B10]\]. A recent study has also shown that endogenous subclinical hyperthyroidism might be considered an additional risk factor for osteoporosis in postmenopausal women, especially for cortical bone, whereas exogenous subclinical hyperthyroidism has no effect on BMD \[[@B11]\]. Post-menopausal women with nodular thyroid disease often undergo continuative and prolonged treatment with LT4 administered at suppressive dosages. Nodular thyroid disease and osteoporosis share common factors: (a) both are present with an elevated frequency in the general population; (b) they are more prevalent in the female sex; (c) the incidence increases with age. Since increased levels of thyroid hormones may contribute to bone demineralization.

The aim of this study was to evaluate the effects of treatment with a fixed dose of LT4 on BMD in physiological post-menopausal women with normofunctioning nodular thyroid disease, compared to women, the same average age, who did not receive LT4.

2. Patients and Methods {#sec2}
=======================

2.1. Patient Selection {#sec2.1}
----------------------

To examine the effects of the treatment with LT4 on the BMD, 110 (range 50--55 years, average age 53), natural post-menopausal patients with normo-functioning uninodular or multinodular benign thyroid disease were enrolled, after informed consent, if they:had last regular menstruation less than 5 years before;had a normal T-score (≥1 SD);did not have secondary causes of bone demineralization (genetic, endocrine-metabolic, osteoarticular, hematologic, neoplastic, gastrointestinal, drug administration, and/or prolonged immobilization);did not receive LT4 treatment in the previous two years;did not have a history positive for vertebral fracture.

Following preliminary evaluation, all patients were prescribed LT4 at the fixed dose of 1.6 *μ*g/kg/die.

Exclusion CriteriaSurgical menopause, hormone replacement therapy in the last two years and autoimmune thyroid disorders.

2.2. Control Group {#sec2.2}
------------------

Fifty women of the same average age (range 50--55 yrs, average age 53.5), having their last menstruation less than 5 years before (last referred menstruation), with normal T-score (≥1 SD) and not receiving LT4.

None of the patients assumed any drugs.

2.3. Instrumental and Laboratory Evaluation {#sec2.3}
-------------------------------------------

All patients underwent evaluation of BMD by dual X-ray absorptiometry of the lumbar vertebrae (Bone Densitomiters Gammadensit X-ray, l\'ACN Scientific Laboratories; Cerro Maggiore (MI) Italy) before LT4 treatment was begun (T0) and 2 years after treatment (group A) and/or followup (group B) (T2). The serum levels of TSH (ECLIA, Roche Diagnostics, Monza (MI), Italy), FT4, FT3 (ECLIA, Roche Diagnostics, Monza (MI), Italy), AbTG and AbTPO (ECLIA, Roche Diagnostics, Monza (MI), Italy), were evaluated at T0 and at T2. All the patients enrolled underwent measurements of calcium serum levels (colorimetric method; Roche Diagnostics, Monza (MI), Italy), 24 h urinary calcium concentration (colorimetric method, Roche Diagnostics, Monza (MI), Italy), serum alkaline phosphatase (AP) bone isoenzyme levels (enzymatic method; Metra TM BAP EIA) and 24 h urinary hydroxyproline concentration (colorimetric method; LTA; Bussero (MI), Italy) at T0 and T2.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The results are reported as mean ± SEM throughout the study. According to LT4 therapy, patients were divided into 2 groups: a group which received LT4 therapy (group A) and group which did not receive any treatment (group B). The statistical analysis was performed using the Student *t*-test for paired or unpaired data, as suitable. The odd\'s ratios of the risk factors in relationship to bone mineralization loss were determined. The statistical significance was accepted when the value of *P* resulted lower than 0.05.

3. Results {#sec3}
==========

The patients enrolled had a mean age of 53.4 years (range 50--55 yrs). As expected, the treatment with LT4 caused a significant reduction of TSH serum levels (*P*\< 0.0001) at T2. At T0, the group A patients had a mean T-score of −0.22 ± 0.07 which decreased significantly to −1.02 ± 0.10 at T2 (*P*\< 0.001). The total calcium concentration in serum and 24 h urine after treatment with LT4 did not change significantly in comparison to the pretreatment values (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). The serum levels of AP and the amount of hydroxyproline excreted with the 24 h urine increased significantly (*P*\< 0.0001) during treatment with LT4 (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). The impact of some risk factors for osteoporosis was evaluated on the BMD of the patients treated with LT4. The results of this analysis are shown in [Table 3](#tab3){ref-type="table"}. A positive history for osteoporosis, smoking habit, and length of menopause did not give a significant odd ratio. In contrast, the following risk factors turned out to influence in a statistically significant manner the BMD: BMI \< 19 kg/m^2^, the onset of menarche after the age of 15 years, a positive history for periods of prolonged amenorrhea, nulliparity.

4. Discussion {#sec4}
=============

The results of this study showed that patients with nodular thyroid disease treated with a fixed dose of LT4 have a slight, but highly significant reduction of the BMD after two years of treatment. Forty-one out of 110 women (37.3%) had osteopenia at T2 (tra −1 e T-score −2.5 SD); in the control group osteopenia at T2 occurred in 6% of patients. The loss of BMD appeared mainly related to the following factors: (1) BMI \< 19 kg/m^2^; (2) menarche onset after the 15th year of age; (3) a clinical history positive for periods of secondary amenorrhea; (4) nulliparity.

In parallel with the modifications of the BMD after two years of LT4 treatment, it was also observed an increase in 24 h urinary hydroxyproline concentration, suggestive of increased osteoclastic activity, and increased serum AP levels, an index of increased osteoblastic activity. Altogether therefore these data suggest that LT4 treatment increases bone metabolic turnover, with prevalence of the re-absorption phase. The results of this study, therefore, favor the hypothesis that the treatment with suppressive dosages of LT4, frequent in the clinical practice of women in menopause with nodular thyroid disease, is a risk factor for the progression of bone demineralization. In particular, women with the following predisposing risk factors: thinness, delayed menarche, periods of secondary amenorrhea during the reproductive age, nulliparity, are likely to undergo a more profound negative impact of LT4 treatment on BMD.

Contrasting results have been published about the role played by LT4 treatment on the BMD. The discrepancies between the various studies are determined by methodological bias, such as (a) progressive reduction of the LT4 dosage prescribed to women which by itself may justify a reduced risk for bone loss; (b) inclusion of patients with a clinical history positive for hypo- or hyper-thyroidism which has been reported to impair BMD \[[@B12]\]; (c) differences in the duration of the treatment; (d) heterogeneous methods and site of BMD evaluation; (e) lack of data collection relative to the role of other possible interfering factors; (f) inclusion of pre-menopausal women; (g) unmatched controls (for body weight, age at menarche and at menopause, calcium dietary intake, smoking habits, alcohol intake, exercise, etc.). A meta-analysis study, published in 1996, reviewed 41 controlled cross-sectional studies, including about 1250 patients, concerning the impact of thyroid hormone therapy on BMD. Suppressive LT4 therapy was associated with significant bone loss in postmenopausal women (but not in premenopausal women), whereas, conversely, replacement therapy was associated with bone loss in premenopausal women (spine and hip), but not in postmenopausal women. The detrimental effect of thyroid hormones appeared more marked on cortical bone than on trabecular bone \[[@B13]\]. We will briefly review the major studies appeared in literature afterwards which can be divided into those showing a detrimental effect of LT4 on BMD and those showing no such an effect \[[@B16]--[@B17]\]. A summary of the main features of these studies is reported in [Table 4](#tab4){ref-type="table"}.

A careful selection of a group of post-menopausal women with thyroid nodular disease under treatment with a fixed doses of LT4 allowed us to show that this treatment causes a slight but significant reduction of BMD. In addition, BMD reduction was associated with the following osteoporosis risk factors: BMI \< 19 kg/m^2^, the onset of menarche after the age of 15 years, history positive for period of amenorrhea, and nulliparity. In consideration that LT4 treatment is effective in a low percentage of patients with benign thyroid nodules, estimated to be 10--20% \[[@B27]\], a careful benefit/risk evaluation has to be taken into account before LT4 treatment is prescribed, particularly when other risk factors for bone demineralization are present. The present study confirms comments from our previous article, conducted on 99 post-menopausal women \[[@B28]\], all of them receiving LT4, prospectively evaluated after one-year treatment. In addition, to previous data, the present study consider an homogeneous control group, for average age and clinical features, including only physiological menopause limited to 5-year history (last menstruation). It also increase to two-year observation length of women receiving therapy, allowing a better understanding of the phenomenon. Moreover, this study excludes conditioning anamnestic factors such as: surgical menopause, HRT, andautoimmune thyroid disorders.

###### 

Bone mineral density (BMD), TSH and markers of osteoblastic and osteoclastic activities before (T0) and two years (T2) after treatment with L-thyroxin in 110 postmenopausal patients with nodular thyroid disease.

                                                    T0             T1
  ------------------------------------------------- -------------- ----------------
  BMD (T-score)                                     −0.22 ± 0.07   −1.02 ± 0.10\*
  TSH (*μ*IU/mL)                                    1.3 ± 0.1      0.8 ± 0.07\*
  Serum calcium concentration (mg/dL)               8.9 ± 0.02     8.8 ± 0.03
  Urinary calcium excretion (mg/24 h)               183.2 ± 3.1    190.4 ± 3.3
  Alkaline phosphatase (UI/L)                       169.7 ± 2.5    188.6 ± 2.3\*
  Urinary hydroxyproline excretion (mg/m^2^/24 h)   12.8 ± 0.6     15.7 ± 0.4\*

\**P* \< 0.001 versus T0.

Normal values: TSH: 0.49--4.67 *μ*U/L; serum calcium concentration: 8.2--10.5 mg/dL; urinary calcium excretion: 50--250 mg/24 h; alkaline phosphatase: 98--279 UI/L; urinary hydroxyproline excretion (22--65 yrs): 6--22 mg/m^2^/24 h.

###### 

Bone mineral density (BMD), TSH and markers of osteoblastic and osteoclastic activities before (T0) and two years (T2) after followup in 50 postmenopausal patients did not receive any therapy (control group).

                                                    T0             T1
  ------------------------------------------------- -------------- --------------
  BMD (T-score)                                     −0.27 ± 0.02   −0.30 ± 0.07
  TSH (*μ*IU/mL)                                    1.4 ± 0.2      1.5 ± 0.04
  Serum calcium concentration (mg/dL)               9.1 ± 0.06     9.2.8 ± 0.01
  Urinary calcium excretion (mg/24h)                144.2 ± 2.1    146.4 ± 2.2
  Alkaline phosphatase (UI/L)                       160.7 ± 1.5    160.9 ± 1.2
  Urinary hydroxyproline excretion (mg/m^2^/24 h)   13.1 ± 0.6     13.0 ± 0.1

\**P* \< 0.001 versus T0.

Normal values: TSH: 0.49--4.67 *μ*U/L; serum calcium concentration: 8.2--10.5 mg/dL; urinary calcium excretion: 50--250 mg/24 h; alkaline phosphatase: 98--279 UI/L; urinary hydroxyproline excretion (22--65 yrs): 6--22 mg/m^2^/24 h.

###### 

Odd\'s ratio of each risk factor.

  Risk factors           *n*   T score \<--1   T score \> −1 \< −2.5   Odd\'s ratio   95% confidence interval   Chi square (*P* value)
  ---------------------- ----- --------------- ----------------------- -------------- ------------------------- ------------------------
  Familiarity +          48    26              16                      1.0            0.45--2.4                 NS
  Familiarity −          62    36              21                                                               
  BMI \< 19 kg/m^2^      41    11              24                      8.6            3.55--21.87               \<0.0005
  BMI ≥ 19 kg/m^2^       69    51              13                                                               
  Menarche \> 15 years   50    20              24                      3.9            1.64--9.16                \<0.0005
  Menarche \< 15 years   60    42              13                                                               
  Amenorrhoea +          52    15              26                      7.4            2.97--18.47               \<0.0005
  Amenorrhoea −          58    47              11                                                               
  Nulliparity +          48    12              25                      8.7            3.41--22.07               \<0.0005
  Nulliparity −          62    50              12                                                               
  Smoking +              40    17              16                      2.0            0.86--4.75                NS
  Smoking −              70    45              21                                                               

NS: not statistically significant.

###### 

Summary of the principal characteristics of the main studies exploring the effects of the treatment with L-thyroxin on the bone mineral density (BMD).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                 Thyroid disease                      Number of patients   Type of treatment   Length of treatment (years)   Menopausal status   Effect on BMD
  --------------------------------------- ------------------------------------ -------------------- ------------------- ----------------------------- ------------------- -----------------------------
  Affinito et al., 1996 \[[@B16]\]        Hypothyroidism                       54                   Suppressive         Various                       After               Decreased

  Baldini et al., 2002 \[[@B25]\]         Nontoxic goiter                      43                   Suppressive         ≥2                            Before and after    Unchanged

  Chen et al., 2004 \[[@B19]\]            Cancer (thyroidectomy)               69                   Suppressive         7.3 ± 3                       44 before\          Decreased
                                                                                                                                                      25 after            

                                          Nodular goiter                       32                   None                NA                                                None

  Foldes et al., 1993 \[[@B14]\]          Subclinical hyperthyroidism          37                   None                NA                            Before and after    None

                                          Toxic adenoma                        22                   None                NA                                                Decreased in postmenopausal

  Gorres et al., 1996 \[[@B22]\]          Cancer (thyroidectomy)               65                   Suppressive                                       15 before\          Unchanged
                                                                                                                                                      32 after\           
                                                                                                                                                      18 men              

  Hadji et al., 2000 \[[@B20]\]           Nontoxic goiter and hypothyroidism   156                  Substitutive        \>5                           Before and after    Slightly decreased

  Heijckmann et al., 2005 \[[@B26]\]      Cancer                               59                   Suppressive         \>6                                               Unchanged

  Kung and Yeung, 1996 \[[@B15]\]         Cancer (thyroidectomy)               46                   Suppressive         2                             After               Decreased

  Larijani et al., 2004 \[[@B21]\]        Thyroid nodules                      41                   Substitutive        \>1                           Before              Unchanged

  Mikosch et al., 2001 \[[@B24]\]         Cancer                               98                   Suppressive                                                           Unchanged

  Nuzzo et al., 1998 \[[@B23]\]           Nontoxic goiter                      40                   Suppressive         1.5--14                       Before              Unchanged

  Sijanovic and Karner, 2001 \[[@B18]\]   Cancer (thyroidectomy)               19                   Suppressive         9                             Before              Decreased

  Toivonen et al., 1998 \[[@B17]\]        Cancer (thyroidectomy)               29                   Suppressive         9--11                         25 women\           Decreased
                                                                                                                                                      4 men               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not applicable.
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